LF is a WHO priority disease and, together with rabies, a major health burden in West Africa. Here we present the development and characterization of an inactivated recombinant LASV and rabies vaccine candidate (LASSARAB) that expresses a codon-optimized LASV glycoprotein (coGPC) and is ...
There is no vaccine or chemoprophylaxis available for coronaviruses at present.102 Droplet and contact precautions, including the use of face masks, are advisable to prevent transmission. As transmission could be opportunistically airborne, appropriate isolation precautions (in negative-pressure facilities ...
BACKGROUND: Vaccines based on mRNA coding for antigens have been shown to be safe and immunogenic in preclinical models. We aimed to report results of the first-in-human proof-of-concept clinical trial in healthy adults of a prophylactic mRNA-based vaccine encoding rabies virus glycoprotein (CV...
Rabies, caused by rabies virus (RABV), is still the deadliest infectious disease. Mechanism of host immune response upon RABV infection is not yet fully understood. Accumulating evidences suggest that long noncoding RNAs (lncRNAs) plays key roles in host antiviral responses. However, expression prof...
This is especially relevant for oral rabies vaccine baits that are deliberately distributed into the environment. In the current study, survival of an oral rabies virus vaccine, SPBN GASGAS, was examined in excretions from different target and non-target species; red fox, raccoon dog, small ...
The invention relates to a vaccine rabies avirulent, which consists of a mutant avirulent of a strain of virus sad rabic, the glycoprotein is in position, 333 a natural amino acid whose position is different from those of the transporter by at least two nucleotides. & lt; br / > ...
The invention relates to a vaccine rabies avirulent, which consists of a mutant avirulent of a strain of virus sad rabic, the glycoprotein is in position, 333 a natural amino acid whose position is different from those of the transporter by at least two nucleotides. & lt; br / > ...
Much of the evidence for NSEs comes from observational studies with a high risk of bias, and there is a clear need for new data from randomised controlled trials. Recently, it was proposed that rabies vaccine has protective NSEs in people and in animals. The aim of the proposed study is ...
Much of the evidence for NSEs comes from observational studies with a high risk of bias, and there is a clear need for new data from randomized controlled trials. Recently, it was proposed that rabies vaccine has protective NSEs in people and in animals. The aim of the proposed study is ...
Rabies vaccine–a non-live vaccine–has been associated with protection against unrelated central nervous system infections. Data from randomized controlled trials are needed to assess this effect against other illnesses. This phase IV, single-site, participant-blinded, randomized, placebo-controlled ...